Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients
Seminars in Arthritis and Rheumatism, Volume 46, No. 1, Year 2016
Notification
URL copied to clipboard!
Description
Objective To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA). Methods Multicenter study of SpA-related uveitis refractory to at least 1 immunosuppressive drug. The main outcome variables were degree of anterior and posterior chamber inflammation, visual acuity, and macular thickness. Results A total of 15 patients (13 men/2 women; 18 affected eyes; mean age 39 ± 6 years) were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n = 8), psoriatic arthritis (n = 6) and non-radiographic axial SpA (n = 1). The ocular involvement patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. Before GLM they have received methotrexate (n = 13), sulfasalazine (n = 6), pulses of methylprednisolone (n = 4), azathioprine (n = 3), leflunomide (n = 2), and cyclosporine (n = 1). Overall, 10 of them had also been treated with TNF-α blockers; etanercept (n = 7), adalimumab (n = 7), infliximab (n = 6), and certolizumab (n = 1). GLM was given at the standard dose (50 mg/sc/monthly) as monotherapy (n = 7) or in combination with conventional immunosuppressive drugs (n = 8), mainly methotrexate. Most patients had rapid and progressive improvement of intraocular inflammation parameters. The median number of cells in the anterior chamber at 2 years [0 (0–0)] was significantly reduced compared to baseline findings [1 (0–3); p = 0.04]. The mean best corrected visual acuity value also improved (0.84 ± 0.3 at 2 years versus 0.62 ± 0.3 at baseline; p = 0.03). Only minor side effects were observed after a mean follow-up of 23 ± 7 months. Conclusions Our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis. © 2016 Elsevier Inc.
Authors & Co-Authors
Calvo-Río, Vanesa
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Cordero-Coma, Miguel
Spain, Leon
Hospital de León
Veroz, Raúl
Spain, Badajoz
Hospital de Mérida
Loricera, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Vela, María Carmen
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Palmou, Natalia
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Herńandez, José L.
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 70
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1016/j.semarthrit.2016.03.002
ISSN:
00490172
Study Design
Cohort Study
Participants Gender
Male
Female